Bluebird Bio, INC

Gene therapy pioneer bluebird bio has completed its acquisition by investment firms Carlyle and SK Capital, transitioning to a privately held company with new leadership and significant capital backing to scale its commercial operations.

Bluebird Bio has amended its merger agreement with Carlyle and SK Capital, providing stockholders the option to receive either $3.00 per share plus a contingent value right (CVR) of $6.84, or $5.00 per share in cash.

Bluebird Bio has received an unsolicited, non-binding acquisition proposal from Ayrmid Ltd, offering $4.50 per share in cash plus a $6.84 contingent value right, while the company is already subject to a merger agreement with Carlyle and SK Capital Partners.

Bluebird Bio enters a definitive agreement to be acquired by Carlyle and SK Capital, offering stockholders $3.00 per share in cash plus a contingent value right of $6.84 per share upon achieving a net sales milestone.

Bluebird Bio has terminated its sublease agreement with Aventis and sub-sublease agreement with Meta Platforms for space in Cambridge, Massachusetts, effective immediately.

Bluebird Bio has completed a 1-for-20 reverse stock split, effective December 12, 2024, to consolidate its shares and adjust its trading price.

Bluebird Bio's Q1 2025 results show increased product revenue but ongoing losses as the company navigates a pending merger and going concern uncertainties.

Bluebird Bio's Q3 2024 results show a net loss of $60.8 million, alongside a restructuring plan aimed at reducing operating expenses.

Bluebird Bio's Q2 2024 results show increased product revenue but significant net losses and concerns about its ability to continue as a going concern.

Bluebird Bio's first quarter 2024 results show a significant increase in product revenue to $18.6 million, driven by sales of ZYNTEGLO and SKYSONA.

Bluebird Bio's 2024 10-K filing reveals significant losses, going concern doubts, and details of a pending merger with Beacon Parent Holdings, L.P.

Bluebird Bio details its authorized capital stock, including common and preferred shares, and outlines provisions designed to deter unsolicited takeover attempts.

Joseph Vittiglio, Chief Business & Legal Officer of bluebird bio, Inc., has disposed of all his common stock holdings and restricted stock units following the company's merger with Beacon Parent Holdings, L.P., converting them into cash and contingent value rights.

Bluebird Bio director John O. Agwunobi converted his equity holdings, including restricted stock units, into cash and contingent value rights as the company completed its merger and became a wholly owned subsidiary of Beacon Parent Holdings, L.P.

Mark Vachon, a Director of bluebird bio, Inc., has reported the disposition of all his directly held common stock in the company, effective June 2, 2025, as a result of the previously announced merger with Beacon Parent Holdings, L.P.

Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., has reported the conversion of his equity holdings into cash and contingent value rights following the company's merger with Beacon Merger Sub, Inc.

A recent SEC Form 4 filing details bluebird bio Director Najoh Tita-Reid's share transactions, reflecting the company's acquisition by Beacon Parent Holdings, L.P. through a tender offer and subsequent merger.

bluebird bio's President and CEO, Andrew Obenshain, reported the conversion of his equity holdings into cash and contingent value rights as part of the company's acquisition by Beacon Parent Holdings, L.P.

Bluebird Bio is asking stockholders to vote for a reverse stock split to maintain Nasdaq compliance and enable future financing, crucial for reaching cash flow breakeven in the second half of 2025.

Bluebird Bio adjourned its annual meeting to solicit additional votes for a reverse stock split proposal aimed at maintaining Nasdaq listing and securing future financing.

Bluebird Bio is urging its stockholders to vote in favor of a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and enable the company to raise additional capital.

Bluebird Bio is urging stockholders to vote in favor of Proposals 4 and 5, including a reverse stock split and an amendment to the incentive award plan, at the Annual Meeting of Stockholders on November 6, 2024.

Bluebird Bio is addressing a potential delisting from the Nasdaq Global Select Market due to its stock price falling below the minimum bid price requirement and is considering a reverse stock split.

Bluebird Bio has filed a definitive proxy statement with the SEC, indicating upcoming shareholder meetings and voting on key corporate matters.